fda approved glp-1 receptor agonists GLP-1R by the United States and international The Impact of GLP-1 Receptor

The prevalence of obesity in the USA has been increasing over the past few decades, and despite the availability of approved anti-obesity medications (AOMs), people with obesity may not be accessing or receiving treatment at levels consistent with the disease prevalence

Malabsorptive procedures (e.g., RYGB, BPD) significantly reduce absorption areas by bypassing the jejunum or ileum, leading to more severe nutrient deficiencies and bone loss

GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice

Manufactured in the US

Ono, A., Okuma, Y., Hosoi, T

Diab Care 37 , 21492158 (2014)